Decision analysis - Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations

New England Journal of Medicine

Volumn 336, Issue 20, 1997, Pages 1465-1471

  Schrag, Deborah ^a   Kuntz, Karen M ^b   Garber, Judy E ^a   Weeks, Jane C ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; GENE MUTATION; MASTECTOMY; MEDICAL DECISION MAKING; MODEL; OVARIECTOMY; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT;

ADULT; BRCA2 PROTEIN; BREAST NEOPLASMS; DECISION SUPPORT TECHNIQUES; FEMALE; GENES, BRCA1; HUMANS; LIFE EXPECTANCY; MASTECTOMY; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; OVARIECTOMY; PRIMARY PREVENTION; PROBABILITY; TRANSCRIPTION FACTORS;

EID: 0030909527     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199705153362022     Document Type: Article

References (42)

1. Easton DF, Ford D, Bishop DT, Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995;56:265-71.
2. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995;57:1457-62.
3. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Lancet 1994;343:692-5.
4. Struewing IP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
5. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496-504.
6. Kosary CL, Ries LAG, Miller BA, Hankey BF, Harras A, Edwards BK, eds. SEER cancer statistics review, 1973-1992: tables and graphs, Bethesda, Md.: National Cancer Institute, 1995. (NIH publication no. 96-2789.)
7. Greenwald P, Nasca PC, Lawrence CE, et al. Estimated effect of breast self-examination and routine physician examinations on breast-cancer mortality. N Engl J Med 1978;299:271-3.
8. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography: a meta-analysis. JAMA 1995;273:149-54.
9. Bourne TH, Whitehead MI, Campbell S, Royston P, Bhan V, Collins WP. Ultrasound screening for familial ovarian cancer. Gynecol Oncol 1991; 43:92-7
10. Stefanek ME. Bilateral prophylactic mastectomy: issues and concerns. In: Hereditary breast cancer, ovarian and colon cancer. NCI monographs. No. 17 Washington, D.C.: Government Printing Office, 1995:37-42.
11. Eldar S, Meguid MM, Beatty JD. Cancer of the breast after prophylactic subcutaneous mastectomy. Am J Surg 1984;148:692-3.
12. Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: a report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993;71:2751-5.
13. King MC, Rowell S, Love SM. Inherited breast and ovarian cancer: what are the risks? What are the choices? JAMA 1993;269:1975-80.
14. Lerman C, Narod SA, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. JAMA 1996;275:1885-92.
15. Hoskins KF, Stopfer JE, Calzone KA, et al. Assessment and counseling for women with a family history of breast cancer: a guide for clinicians. JAMA 1995;273:577-85.
16. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38.
17. Hollenberg JP. Smltree: the all purpose decision tree builder. Boston: Pratt Medical Group, 1985.
18. Pennisi VR, Capozzi A. Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesthetic Plast Surg 1989;13:15-21.
19. Ziegler LD, Kroll SS. Primary breast cancer after prophylactic mastec tomy. Am J Clin Oncol 1991;14:451-4.
20. Piver MS, Baker TR, Jishi MF, et al. Familial ovarian cancer: a report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 1993;71:Suppl:582-8.
21. Struewing JP, Watson R, Easton DF, Ponder BA, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. In: Hereditary breast cancer, ovarian and colon cancer. NCI monographs. No. 17. Washington, D.C.: Government Printing Office, 1995:33-5.
22. Porter DE, Cohen BB, Wallace MR, et al. Breast cancer incidence, penetrancc and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 1994;81: 1512-5.
23. Porter DE, Dixon M, Smyth E, Steel CM. Breast cancer survival in BRCA1 carriers. Lancet 1993;341:184-5.
24. Eisinger F, Stoppa-Lyonnet D, Longy M, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996;56:471-4.
25. Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, BRCA1 and BRCA2 gene linkage. Cancer 1996;77: 697- 709.
26. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992;339:71-85.
27. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995; 333:1456-61.
28. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: results of 20 years of follow-up. N Engl J Med 1995; 332:901-6.
29. Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer: estimates using decision analysis while awaiting clinical trial results. JAMA 1992;267:2055-61.
30. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial. JAMA 1994;271:1593-7.
31. The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA 1994;271:1587-92.
32. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335:1413-6.
33. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med 1990;322:1021-7
34. Krainer M, Silva-Arrieta S, FitzGerald MG, et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 1997;336:1416-21.
35. Phelan CM, Rebbeck TR, Weber BL, et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeats (VNTR) locus. Nat Genet 1996;12:309-11.
36. Neuhausen SL, Mazoyer S, Friedman L, et al. Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet 1996:58:271-80.
37. Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:1409-15.
38. Tsevat J, Weinstein MC, Williams LW, Tosteson AN, Goldman L. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 1991;83:1194-201. [Erratum, Circulation 1991;84:2610.]
39. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer: a decision-analysis model. N Engl J Med 1991;324:160-8.
40. Smith TJ, Hillner BE. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 1993;11:771-6.
41. Gross TP, Schlesselman JJ. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol 1994;83:419-24.
42. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.